Treatment Implications of Trigeminal Sensitization in Acute and Chronic Migraine: Expert Commentary on Selected Abstracts

W. J. Becker M.D.
{"title":"Treatment Implications of Trigeminal Sensitization in Acute and Chronic Migraine: Expert Commentary on Selected Abstracts","authors":"W. J. Becker \n M.D.","doi":"10.1111/j.1743-5013.2004.10106.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <p>OBJECTIVE: To evaluate the efficacy and tolerability of sumatriptan, 50-mg and 100-mg tablets, compared with the placebo for the treatment of migraine at the first sign of pain.</p>\n <p>PATIENTS AND METHODS: Two identical multicenter randomized, double-blind, placebo-controlled, single-attack studies were conducted from May through November 2000 in adults (aged 18–65 years). Patients treated migraine at the first sign of pain, while pain was mild, but not more than 2 hours after onset with oral sumatriptan, 50 or 100 mg, or matching placebo. The primary end point was pain-free relief at 2 hours after treatment with 50 mg of sumatriptan compared with placebo.</p>\n <p>RESULTS: There were 354 patients in study 1 and 337 patients in study 2. Significantly more patients treated with sumatriptan, 50 and 100 mg, were completely free from pain 2 and 4 hours after the treatment versus patients treated with placebo (at 2 hours, 50% and 57% vs. 29%; at 4 hours, 61% and 68% vs. 30%; for both, <i>p</i> &lt; 0.001). Also, significantly more patients treated with sumatriptan, 50 and 100 mg, were migraine-free (no pain or associated symptoms) versus those treated with placebo at 2 and 4 hours after the treatment (at 2 hours, 43% and 49% vs. 24%; at 4 hours, 54% and 63% vs. 28%; for both, <i>p</i> &lt; 0.001). The incidence of overall adverse events was low with the 50- and 100-mg dose of sumatriptan (placebo, 7%; sumatriptan at 50 mg, 14%; sumatriptan at 100 mg, 16%).</p>\n <p>CONCLUSIONS: Treatment of migraine at the first sign of pain with sumatriptan, 50-mg and 100-mg tablets, provides superior pain-free relief at 2 and 4 hours after the treatment compared with the placebo. Results of these studies suggest that sumatriptan at 100 mg may be more efficacious than at 50 mg when used in the early treatment paradigm. Because these studies were not powered to detect statistical differences between active doses, studies to investigate this finding are warranted.</p>\n </div>","PeriodicalId":100600,"journal":{"name":"Headache Currents","volume":"1 2","pages":"42-46"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1743-5013.2004.10106.x","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Headache Currents","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1743-5013.2004.10106.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE: To evaluate the efficacy and tolerability of sumatriptan, 50-mg and 100-mg tablets, compared with the placebo for the treatment of migraine at the first sign of pain.

PATIENTS AND METHODS: Two identical multicenter randomized, double-blind, placebo-controlled, single-attack studies were conducted from May through November 2000 in adults (aged 18–65 years). Patients treated migraine at the first sign of pain, while pain was mild, but not more than 2 hours after onset with oral sumatriptan, 50 or 100 mg, or matching placebo. The primary end point was pain-free relief at 2 hours after treatment with 50 mg of sumatriptan compared with placebo.

RESULTS: There were 354 patients in study 1 and 337 patients in study 2. Significantly more patients treated with sumatriptan, 50 and 100 mg, were completely free from pain 2 and 4 hours after the treatment versus patients treated with placebo (at 2 hours, 50% and 57% vs. 29%; at 4 hours, 61% and 68% vs. 30%; for both, p < 0.001). Also, significantly more patients treated with sumatriptan, 50 and 100 mg, were migraine-free (no pain or associated symptoms) versus those treated with placebo at 2 and 4 hours after the treatment (at 2 hours, 43% and 49% vs. 24%; at 4 hours, 54% and 63% vs. 28%; for both, p < 0.001). The incidence of overall adverse events was low with the 50- and 100-mg dose of sumatriptan (placebo, 7%; sumatriptan at 50 mg, 14%; sumatriptan at 100 mg, 16%).

CONCLUSIONS: Treatment of migraine at the first sign of pain with sumatriptan, 50-mg and 100-mg tablets, provides superior pain-free relief at 2 and 4 hours after the treatment compared with the placebo. Results of these studies suggest that sumatriptan at 100 mg may be more efficacious than at 50 mg when used in the early treatment paradigm. Because these studies were not powered to detect statistical differences between active doses, studies to investigate this finding are warranted.

三叉神经致敏对急性和慢性偏头痛的治疗意义:专家评论精选摘要
目的:评价舒马曲坦50mg和100mg片剂与安慰剂治疗偏头痛首发疼痛症状的疗效和耐受性。患者和方法:2000年5月至11月,在成年人(18-65岁)中进行了两项相同的多中心随机、双盲、安慰剂对照、单次发作的研究。患者在偏头痛出现疼痛症状时进行治疗,而疼痛是轻微的,但不超过发病后2小时,口服舒马曲坦,50或100毫克,或配套安慰剂。主要终点是与安慰剂相比,50mg舒马曲坦治疗后2小时的无痛缓解。结果:研究1有354例患者,研究2有337例患者。与服用安慰剂的患者相比,服用50 mg和100 mg舒马曲坦的患者在治疗后2小时和4小时完全没有疼痛(2小时,50%和57% vs 29%;4小时时,61%和68% vs. 30%;对于两者,p <0.001)。此外,在治疗后2小时和4小时,接受50和100 mg舒马曲坦治疗的患者与接受安慰剂治疗的患者相比,明显更多的患者无偏头痛(无疼痛或相关症状)(2小时,43%和49% vs. 24%;4小时时,54%和63% vs. 28%;对于两者,p <0.001)。50mg和100mg剂量的舒马曲坦的总体不良事件发生率较低(安慰剂,7%;舒马曲坦50mg, 14%;舒马曲坦100mg, 16%)。结论:与安慰剂相比,舒马曲坦(50mg和100mg片剂)在治疗后2小时和4小时提供了更好的无痛缓解。这些研究的结果表明,在早期治疗模式中,100毫克的舒马曲坦可能比50毫克更有效。由于这些研究没有能力检测活性剂量之间的统计差异,因此调查这一发现的研究是有必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信